Use of sotagliflozin for the treatment of patients with type 1 diabetes mellitus
AssigneeLexicon Pharmaceuticals, Inc.
InventorsPhillip BANKS, Sangeeta SAWHNEY
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of sotagliflozin to improve glycemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI)≥27 kg/m2.
Claims12
A method of improving glycemic control comprising administering to a patient in need thereof a therapeutically effective amount of sotagliflozin or a pharmaceutically acceptable salt thereof, wherein said patient has type 1 diabetes and a Body Mass index (BMI)≥27 kg/m2.
A method of treating type I diabetes comprising administering to a patient in need thereof a therapeutically effective amount of sotagliflozin or a pharmaceutically acceptable salt thereof, wherein said patient has a Body Mass index (BMI)≥27 kg/m2.
A method of improving A1C comprising administering to a patient in need thereof a therapeutically effective amount of sotagliflozin or a pharmaceutically acceptable salt thereof, wherein said patient has a BMI≥27 kg/m2.
Dependencies are inferred from the claim text.